Liraglutide treatment is associated with progression of coronary artery fibrous plaque: a prospective 1-year follow-up study in asymptomatic patients with type 2 diabetes.

Autor: Heinsen LJ; Cardiovascular Research Unit, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark. lauritsheinsen@gmail.com., Pararajasingam G; Cardiovascular Research Unit, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Andersen TR; Cardiovascular Research Unit, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Auscher S; Department of Cardiology, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Sheta HM; Department of Cardiology, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Precht H; Cardiovascular Research Unit, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark.; Institute of Regional Research, University of Southern Denmark, Winsløwsparken 19, 5000, Odense C, Denmark.; Department of Radiology, Lillebaelt Hospital, University Hospitals of Southern Denmark, Sygehusvej 24, 6000, Kolding, Kolding, Denmark., Engdam KB; Cardiovascular Research Unit, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Hangaard J; Department of Endocrinology, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Lambrechtsen J; Department of Cardiology, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark., Knop FK; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Gentofte Hospitalsvej 7, 3rd floor, Gentofte, 2820, Denmark.; Steno Diabetes Center Copenhagen, Gentofte, Denmark.; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Egstrup K; Cardiovascular Research Unit, Odense University Hospital Svendborg, Baagøes Allé 15, Svendborg, 5700, Denmark.
Jazyk: angličtina
Zdroj: BMC cardiovascular disorders [BMC Cardiovasc Disord] 2023 Apr 28; Vol. 23 (1), pp. 214. Date of Electronic Publication: 2023 Apr 28.
DOI: 10.1186/s12872-023-03228-5
Abstrakt: Objective: The objective of this study was to assess the association between clinically indicated liraglutide treatment and coronary artery plaque progression during 1-year follow-up in asymptomatic diabetes.
Methods: Patients were divided into a group receiving liraglutide (Lira+) and a group not receiving liraglutide (Lira-). Coronary computed tomography angiography (CCTA) was performed to assess total atheroma volume (TAV) and subtypes of plaque volumes (dense calcium, fibrous, fibrous-fatty, and necrotic core plaque) and the plaque progression during one year follow-up.
Results: Fifty-five patients (27%) receiving liraglutide and 149 (73%) how did not were included. Changes in TAV during 1-year of follow-up were similar in the two groups (38 ± 180 (Lira+) vs. -1 ± 160 mm 3 (Lira-), P = 0.13). A greater increase in fibrous plaque volume was seen in the Lira + vs. the Lira- group (34 ± 129 vs. -2 ± 101 mm 3 , P = 0.04). Changes over 1-year in the other plaque subtypes were similar in the two groups. Treatment duration of liraglutide was not associated with changes in TAV.
Conclusion: In patients with T2D without known prior coronary artery disease, liraglutide treatment was associated with a significant increase in coronary artery fibrous plaque volume during 1-year follow-up.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: